Vivo Capital and Novo Holdings Lead USD200m Series A for Singapore’s Esco Lifesciences
Source(s): Eco Lifesciences Group
Vivo Capital and Novo Holdings led a USD200m Series A for Esco Lifesciences, a Singapore-based developer of cell and gene therapy tools, with participation from China Investment Corporation and EDBI. Read more